(Reuters) - Pfizer Inc , which in May officially abandoned its bid to buy British rival AstraZeneca Plc , reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.
The largest U.S. drugmaker on Tuesday said it had earned $2.91 billion, or 45 cents per share. That compared with $14.1 billion, or $1.98 per share, a year earlier, when PFIZER (PFE.NY)received more than $10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis
Excluding special items, Pfizer earned 58 cents per share. Analysts on average expected 57 cents, according to Thomson Reuters I/B/E/S.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)
Relacionados
- El consumo de electricidad en el sector industrial crece un 2,5% en Aragón
- La venta en el comercio minorista crece en Canarias un 4,4% en junio
- Las ventas del comercio minorista caen seis décimas en junio en Extremadura, y la ocupación crece un 0,5%
- El gasto de los turistas crece el 7,8% hasta junio y marca otro récord
- Jazztel crece a doble dígito en el segundo trimestre por mejores márgenes
